Last reviewed · How we verify
Weekly TC Chemotherapy
Weekly TC Chemotherapy is a Cytotoxic chemotherapy Small molecule drug developed by Jiangsu Cancer Institute & Hospital. It is currently in Phase 3 development for Metastatic non-small cell lung cancer, Metastatic breast cancer.
Weekly TC chemotherapy involves administering a combination of chemotherapy drugs on a weekly schedule to target rapidly dividing cancer cells.
Weekly TC chemotherapy is a treatment for hormone receptor positive/HER2-negative breast cancer, typically administered in a neoadjuvant setting. It involves the intravenous administration of docetaxel and cyclophosphamide on a weekly schedule.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Weekly TC Chemotherapy |
|---|---|
| Sponsor | Jiangsu Cancer Institute & Hospital |
| Drug class | Cytotoxic chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This treatment modality leverages the cytotoxic effects of chemotherapy agents to induce cell death in cancerous tissues. The weekly schedule aims to maintain a consistent and sustained exposure to the drugs, potentially enhancing their efficacy.
Approved indications
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
Common side effects
- Neutropenia
- Thrombocytopenia
- Nausea and vomiting
- Fatigue
Key clinical trials
- Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer (PHASE2)
- Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study (PHASE3)
- RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (PHASE1, PHASE2)
- RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial (PHASE2)
- Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial） (PHASE2)
- A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer (PHASE3)
- Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer (PHASE3)
- Neoadjuvant Treatment of Breast Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Weekly TC Chemotherapy CI brief — competitive landscape report
- Weekly TC Chemotherapy updates RSS · CI watch RSS
- Jiangsu Cancer Institute & Hospital portfolio CI
Frequently asked questions about Weekly TC Chemotherapy
What is Weekly TC Chemotherapy?
How does Weekly TC Chemotherapy work?
What is Weekly TC Chemotherapy used for?
Who makes Weekly TC Chemotherapy?
What drug class is Weekly TC Chemotherapy in?
What development phase is Weekly TC Chemotherapy in?
What are the side effects of Weekly TC Chemotherapy?
Related
- Drug class: All Cytotoxic chemotherapy drugs
- Manufacturer: Jiangsu Cancer Institute & Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic non-small cell lung cancer
- Indication: Drugs for Metastatic breast cancer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing